OncoMatch/Clinical Trials/NCT06532799
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Is NCT06532799 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for stomach cancer.
Treatment: Tumor Infiltrating Lymphocytes (TIL) · Cyclophosphamid · Fludarabine · Interleukin-2 · Pembrolizumab — This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory stomach and esophageal cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has shown significant promise in treating unresectable or metastatic melanoma by leveraging the patient's own immune cells to target and destroy cancer cells. This study aims to apply a similar approach to stomach and esophageal cancers. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody that targets the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to provide a novel, personalized treatment option for patients with limited therapeutic alternatives.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Disease stage
Metastatic disease required
At least 1 evaluable tumor lesion
Performance status
KARNOFSKY OR ECOG 0–2
Karnofsky≥60% or ECOG score 0-2
Prior therapy
Must have received: standard treatment regimens
Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.
Cannot have received: any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics
Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs
Lab requirements
Blood counts
Absolute count of white blood cells ≥2.5×10^9/L; neutrophils ≥1.5×10^9/L; lymphocytes ≥0.7×10^9/L; platelets ≥100×10^9; hemoglobin ≥90 g/L; APTT ≤1.5xULN; INR ≤1.5xULN
Kidney function
Serum creatinine ≤1.5mg/dL (or ≤132.6μmol/L), or clearance rate ≥50mL/min
Liver function
Serum ALT/AST ≤3×ULN (subjects with liver metastasis ≤3×ULN); Total bilirubin ≤1.5×ULN
Cardiac function
No significant cardiovascular anomalies (NYHA Grade III or IV CHF, low blood pressure, uncontrollable symptomatic coronary artery diseases, EF <35%, severe arrhythmia, second-third degree AV block)
Hematology and Chemistry（within 7 days prior to enrollment）: Absolute count of white blood cells≥2.5×10^9/L; neutrophils≥1.5×10^9/L; lymphocytes ≥0.7×10^9/L; platelets≥100×10^9; hemoglobin≥90 g/L; APTT ≤1.5xULN; INR ≤1.5xULN; Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min; Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN); Totol bilirubin≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify